About Pnn Medical
The company was founded in 1987 under the name Engineers & Doctors A/S, reflecting a close collaboration between engineering expertise and clinical experience from the very beginning. From its early days, the company focused on addressing unmet needs in urology by combining medical insight with technical innovation.
All products developed by Pnn Medical are based on the principles of minimally invasive treatment.
In 2007, the company changed its name to Pnn Medical A/S, inspired by the principle of Primum Non Nocere. The Latin phrase Primum Non Nocere means “first, do no harm”. It expresses a fundamental principle in medicine, reflecting care, responsibility, and humility in the treatment of patients. This principle has long guided Pnn Medical in its work to develop less invasive, yet effective, alternatives to major surgery. The new name was chosen to clearly express the values that had guided the company since its founding. While the name evolved, the overall goal remained unchanged: to develop simple, safe, and reliable alternatives to major surgical procedures.
Quality without compromise
The principle of Primum Non Nocere is fundamental to the way Pnn Medical approaches the development and production of medical devices. Careful consideration of patient safety, clinical responsibility, and long-term reliability guides decisions throughout the development process.
All products developed by Pnn Medical are based on the principles of minimally invasive treatment. This approach is intended to reduce the physical impact of treatment on patients while supporting efficient clinical workflows for healthcare professionals. Considerations such as treatment duration and recovery time are taken into account during product design and development.
Our mission
Pnn Medical’s mission is to help patients return more quickly to their daily routines by continuously seeking ways to reduce treatment complexity through safe, simple, and reliable solutions.
Milestones
A brief history of Pnn Medical, highlighting key developments in the company’s evolution.
1987
Establishment of E&D:
Engineers & Doctors A/S was founded by polymer engineer Erik Othel-Jacobsen and medical doctor Henrik Harboe. In collaboration with Herlev University Hospital in Copenhagen, the company developed its first generation urological stent, Prostakath, marking the beginning of its work within minimally invasive urological solutions.
1990
Establishment of Wallsten Medical:
Swedish inventor and entrepreneur Hans Wallstén, MSc and Doctor h.c., who pioneered self-expanding stents for occlusive diseases during the 1980’s, founded Wallsten Medical SA in Morges, Switzerland. The company focused on the development of medical devices within gynaecology and urology, including Cavaterm™ and Wallterm™.
1992
Introduction of the second generation Memokath™:
The second generation urological stebt, the Memokath™ was introduced. Memokath™ was developed as a biocompatible nickel-titanium programme using shape memory technology for the treatment of urinary tract obstruction and prostate related conditions, representing an important development within minimally invasive urological treatment.
1995
Introduction of the third generation Memokath™ stent:
The third generation of Memokath™ stent was marketed for the treatment of obstruction in the ureteric level.
1997
Establishment of SMP GmbH, Germany:
The German company SMP GmbH was Co-established to secure full control over the manufacturing of the Memokath™ product line.
2004
Memocore™ study:
In collaboration with the University Hospital Aalborg, a clinical study on the use of stents as marker in external beam radiation of prostate cancer is initiated.
2005
Merger between Engineers & Doctors A/S and Wallsten Medical SA:
Following significant growth and increasing focus on minimally invasive treatment, Engineers & Doctors A/S and Wallsten Medical SA merged in May 2005, combining expertise and development efforts within urology.
2007
New Identity:
The company changed its name to Pnn Medical A/S, reflecting the principle of Primum Non Nocere (“first, do no harm”). At the same time, a new corporate identity was introduced, marking a new phase in the company’s development.
2009
Demerger:
It was decided to demerge the Danish and the Swiss part of the company into two separate companies.
2013
Production relocated to Denmark:
Production was relocated to Denmark, marking an important step in the company’s manufacturing history.
